Pioglitazone is an effective treatment for patients with post‑stroke depression combined with type 2 diabetes mellitus

Hu,Yaozhi; Xing,Haiyan; Dong,Xiaomeng; Lu,Wenxian; Xiao,Xinxing; Gao,Lilin; Cui,Minghu; Chen,Jinbo

doi:10.3892/etm.2015.2593

September-2015 Volume 10 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2015 Volume 10 Issue 3

Full Size Image

Article

Pioglitazone is an effective treatment for patients with post‑stroke depression combined with type 2 diabetes mellitus

Authors:
- Yaozhi Hu
- Haiyan Xing
- Xiaomeng Dong
- Wenxian Lu
- Xinxing Xiao
- Lilin Gao
- Minghu Cui
- Jinbo Chen
View Affiliations / Copyright

Affiliations: Department of Neurology, Binzhou Medical University Affiliated Hospital, Binzhou, Shandong 256603, P.R. China, Department of Intensive Care Unit, Binzhou Peoples' Hospital, Binzhou, Shandong 256603, P.R. China, Department of Psychiatry, Binzhou Medical University Affiliated Hospital, Binzhou, Shandong 256603, P.R. China
Pages: 1109-1114
|
Published online on: June 24, 2015

https://doi.org/10.3892/etm.2015.2593
Expand metrics +

Abstract

The antidepressive effects of the antidiabetic medicine, pioglitazone, were recently reported in several studies. These effects may ameliorate the depressive symptoms of patients with post‑stroke depression (PSD). The present study aimed to evaluate the antidepressive effect of pioglitazone in patients with PSD combined with type 2 diabetes. A total of 118 consecutive patients with stroke who had depression were studied for an average of 3 months. The Diagnostic and Statistical Manual of Mental Disorders (fourth edition) was used to assess whether a patient was depressed or not. The severity of depression was evaluated by the Hamilton depression rating scale (HAMD). In accordance with their HAMD scores, the 118 patients were divided into a severe depression group (n=40) and a mild and moderate (MM) depression group (n=78). These subjects were then divided into pioglitazone [30 mg once daily (qd)] and metformin (0.5 g twice daily) subgroups. All patients were given fluoxetine (20 mg qd). Follow‑up evaluations, which included HAMD scores, activities of daily living (ADL) scores, fasting blood glucose (FBG) levels and fasting insulin (FINS) levels, were conducted on the first and third month following the beginning of the treatment. In the MM depression group, the HAMD score in the pioglitazone subgroup was lower than that in the metformin subgroup following treatment for 1 or 3 months. In the severe depression group, the HAMD score in the pioglitazone subgroup was lower than that in the metformin subgroup following 3 months of treatment. The FINS levels of the pioglitazone subgroup gradually decreased in the 3 months of treatment. No noticeable improvement was observed in the ADL scores and FBG values. In conclusion, the results of the current study demonstrate that pioglitazone effectively decreased HAMD scores and FINS values in patients with PSD, suggesting that pioglitazone may be useful for the treatment of patients with PSD combined with type 2 diabetes.

View Figures

View References

1	Morris PL, Robinson RG and Raphael B: Prevalence and course of depressive disorders in hospitalized stroke patients. Int J Psychiatry Med. 20:349–364. 1990. View Article : Google Scholar : PubMed/NCBI
2	Turner A, Hambridge J, White J, et al: Depression screening in stroke: a comparison of alternative measures with the structured diagnostic interview for the diagnostic and statistical manual of mental disorders, fourth edition (major depressive episode) as criterion standard. Stroke. 43:1000–1005. 2012. View Article : Google Scholar : PubMed/NCBI
3	Smith RC, Jin H, Li C, et al: Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. Schizophr Res. 143:18–24. 2013. View Article : Google Scholar : PubMed/NCBI
4	Kashani L, Omidvar T, Farazmand B, et al: Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology. 38:767–776. 2013. View Article : Google Scholar : PubMed/NCBI
5	Kemp DE, Ismail-Beigi F, Ganocy SJ, et al: Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord. 136:1164–1173. 2012. View Article : Google Scholar : PubMed/NCBI
6	Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia MJ and Akhondzadeh S: Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: Randomized double-blind placebo-controlled trial. Neuropsychopharmacology. 37:2093–2100. 2012. View Article : Google Scholar : PubMed/NCBI
7	Pettersson A, Bengtsson Boström K, Gustavsson P and Ekselius L: Which instruments to support diagnosis of depression have sufficient accuracy? A systematic review. Nord J Psychiatry. March 3–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
8	Jia J and Chen S: Brain vessel diseaseNeurology. 7th. People's Medical Publishing House; Beijing, China: pp. 1992013
9	Zimmerman M, Martinez JH, Young D, Chelminski I and Dalrymple K: Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 150:384–388. 2013. View Article : Google Scholar : PubMed/NCBI
10	Schneider MA and Schneider MD: Recognizing poststroke depression. Nursing. 42:60–63. 2012. View Article : Google Scholar : PubMed/NCBI
11	Poynter B, Shuman M, Diaz-Granados N, Kapral M, Grace SL and Stewart DE: Sex differences in the prevalence of post-stroke depression: a systematic review. Psychosomatics. 50:563–569. 2009. View Article : Google Scholar : PubMed/NCBI
12	Kemp DE, Ismail-Beigi F and Calabrese JR: Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. Am J Psychiatry. 166:6192009. View Article : Google Scholar : PubMed/NCBI
13	Salehi-Sadaghiani M, Javadi-Paydar M, Gharedaghi MH, et al: NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice. Psychopharmacology (Berl). 223:345–355. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sadaghiani MS, Javadi-Paydar M, Gharedaghi MH, Fard YY and Dehpour AR: Antidepressant-like effect of pioglitazone in the forced swimming test in mice: The role of PPAR-gamma receptor and nitric oxide pathway. Behav Brain Res. 224:336–343. 2011. View Article : Google Scholar : PubMed/NCBI
15	Tamayo T, Jacobs DR Jr, Strassburger K, et al: Race-and sex-specific associations of parental education with insulin resistance in middle-aged participants: the CARDIA study. Eur J Epidemiol. 27:349–355. 2012. View Article : Google Scholar : PubMed/NCBI
16	Austin AW, Gordon JL, Lavoie KL, Arsenault A, Dasgupta K and Bacon S: Differential association of insulin resistance with cognitive and somatic symptoms of depression. Diabet Med. 31:994–1000. 2014. View Article : Google Scholar : PubMed/NCBI
17	Hardy OT, Czech MP and Corvera S: What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes. 19:81–87. 2012. View Article : Google Scholar : PubMed/NCBI
18	TODAY Study Group, . Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β -cell function in TODAY. Diabetes Care. 36:1749–1757. 2013. View Article : Google Scholar : PubMed/NCBI
19	Badaru UM, Ogwumike OO, Adeniyi AF and Olowe OO: Variation in functional independence among stroke survivors having fatigue and depression. Neurol Res Int. 2013:8429802013. View Article : Google Scholar : PubMed/NCBI
20	Robinson RG and Spalletta G: Poststroke depression: a review. Can J Psychiatry. 55:341–349. 2010.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Pioglitazone is an effective treatment for patients with post‑stroke depression combined with type 2 diabetes mellitus

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles